Ethics in nanomedicine.
David B. Resnik,Sally S. Tinkle +1 more
TL;DR: It is important to proactively address the ethical, social and regulatory aspects of nanomedicine in order to minimize its adverse impacts on the environment and public health and also to avoid a public backlash.
read more
About: This article is published in Nanomedicine: Nanotechnology, Biology and Medicine. The article was published on 08 Jun 2007. and is currently open access. The article focuses on the topics: Kaposi's sarcoma & Liposomal daunorubicin.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges
Francisco Rodríguez,Pablo Caruana,Noa de la Fuente,Pia Español,M. Idoia Gámez,Josep Balart,Elisa Llurba,Ramon Rovira,Raúl Ruiz,Cristina Martin-Lorente,José Luis Corchero,María Virtudes Céspedes +11 more
TL;DR: An overview of the approved nanomedicine for cancer treatment and the rationale behind their designs and applications is provided and the new approaches that are currently under investigation are highlighted, focusing on the tumor microenvironment and tumor disseminate cells as the most attractive and effective strategies for cancer treatments.
Artificial Intelligence and Machine Learning Empower Advanced Biomedical Material Design to Toxicity Prediction
Ajay Singh,Daniel Rosenkranz,Mohammad Hasan Dad Ansari,Rishabh Singh,Anurag Kanase,Shubham Pratap Singh,Blair Johnston,Jutta Tentschert,Peter Laux,Andreas Luch +9 more
- 01 Dec 2020
TL;DR: A comprehensive review of the potential, reality, challenges, and future advances that artificial intelligence (AI) and machine learning (ML) present are described to aid the understanding of nano–bio interactions from environmental and health and safety perspectives.
111
Overcoming Physiological Barriers to Nanoparticle Delivery-Are We There Yet?
Oliver S. Thomas,Wilfried Weber +1 more
TL;DR: This review discusses physiological barriers a nanocarrier must overcome in order to reach its target, with an emphasis on cancer nanomedicine.
Intelligent micro-/nanorobots as drug and cell carrier devices for biomedical therapeutic advancement: Promising development opportunities and translational challenges.
TL;DR: Although still an emerging area, MNRs are steadily becoming a realistic prospect as vital future therapeutic tools for a vast array of biomedical applications, particularly those related to patient safety and personalized medicine approaches, areas that require the design of safe innovative materials.
97
Drug Delivery Interfaces in the 21st Century: From Science Fiction Ideas to Viable Technologies
TL;DR: The progression of the field toward technologies that are now beginning to capture aspects of this early vision of drug delivery are described, focusing on the two most prominent types of systems: the intravascular micro/nano drug carriers for delivery to the site of pathology and drug-loaded implantable devices that facilitate release with the predefined kinetics or in response to a specific cue.
93
References
Nanotoxicology: An Emerging Discipline Evolving from Studies of Ultrafine Particles
TL;DR: Results of older bio-kinetic studies with NSPs and newer epidemiologic and toxicologic studies with airborne ultrafine particles can be viewed as the basis for the expanding field of nanotoxicology, which can be defined as safety evaluation of engineered nanostructures and nanodevices.
What Makes Clinical Research Ethical
TL;DR: 7 requirements are proposed that systematically elucidate a coherent framework for evaluating the ethics of clinical research studies and are universal, although they must be adapted to the health, economic, cultural, and technological conditions in which clinical research is conducted.
The emerging nanomedicine landscape
TL;DR: A global survey of companies pursuing 'nanomedicine' indicates that nanotechnology is taking root in the drug and medical device industry.
1.6K
Safe handling of nanotechnology
Andrew D. Maynard,Robert Aitken,Tilman Butz,Vicki L. Colvin,Ken Donaldson,Günter Oberdörster,Martin A. Philbert,John Ryan,Anthony Seaton,Vicki Stone,Sally S. Tinkle,Lang Tran,Nigel J. Walker,David B. Warheit +13 more
TL;DR: The pursuit of responsible nanotechnologies can be tackled through a series of grand challenges, argue Andrew D. Maynard and his co-authors, and if they and their colleagues can rise to these challenges the true extent of any risks involved should become clear.
1.5K
Nanoparticles – known and unknown health risks
TL;DR: This review provides comprehensive analysis of data available on health effects of nanomaterials and predicts a further rise in consumer products relying on nanotechnology.